We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
- Authors
Tammela, Tuomas; Zarkada, Georgia; Wallgard, Elisabet; Murtomäki, Aino; Suchting, Steven; Wirzenius, Maria; Waltari, Marika; Hellström, Mats; Schomber, Tibor; Peltonen, Reetta; Freitas, Catarina; Duarte, Antonio; Isoniemi, Helena; Laakkonen, Pirjo; Christofori, Gerhard; Ylä-Herttuala, Seppo; Shibuya, Masabumi; Pytowski, Bronislaw; Eichmann, Anne; Betsholtz, Christer; Alitalo, Kari
- Abstract
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, is a key process in several pathological conditions, including tumour growth and age-related macular degeneration. Vascular endothelial growth factors (VEGFs) stimulate angiogenesis and lymphangiogenesis by activating VEGF receptor (VEGFR) tyrosine kinases in endothelial cells. VEGFR-3 (also known as FLT-4) is present in all endothelia during development, and in the adult it becomes restricted to the lymphatic endothelium. However, VEGFR-3 is upregulated in the microvasculature of tumours and wounds. Here we demonstrate that VEGFR-3 is highly expressed in angiogenic sprouts, and genetic targeting of VEGFR-3 or blocking of VEGFR-3 signalling with monoclonal antibodies results in decreased sprouting, vascular density, vessel branching and endothelial cell proliferation in mouse angiogenesis models. Stimulation of VEGFR-3 augmented VEGF-induced angiogenesis and sustained angiogenesis even in the presence of VEGFR-2 (also known as KDR or FLK-1) inhibitors, whereas antibodies against VEGFR-3 and VEGFR-2 in combination resulted in additive inhibition of angiogenesis and tumour growth. Furthermore, genetic or pharmacological disruption of the Notch signalling pathway led to widespread endothelial VEGFR-3 expression and excessive sprouting, which was inhibited by blocking VEGFR-3 signals. Our results implicate VEGFR-3 as a regulator of vascular network formation. Targeting VEGFR-3 may provide additional efficacy for anti-angiogenic therapies, especially towards vessels that are resistant to VEGF or VEGFR-2 inhibitors.
- Publication
Nature, 2008, Vol 454, Issue 7204, p656
- ISSN
1476-4687
- Publication type
Journal Article
- DOI
10.1038/nature07083